Hjem › Plateepitelcancer i hode og hals › Virginia › Richmond
Kliniske studier for Plateepitelcancer i hode og hals i Richmond, VA
12 studier for Plateepitelcancer i hode og hals søker deltakere på steder i og rundt Richmond (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
RekruttererFase 2/3
- Site #0129, Richmond
- Site #0138, Richmond
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
RekruttererFase 3
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
RekruttererFase 2
- VCU Massey Comprehensive Cancer Center, Richmond
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RekruttererFase 2
- Virginia Cancer Institute, Richmond
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
RekruttererFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Virginia Commonwealth University Massey Cancer Center, Richmond
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
RekruttererFase 2
- VCU Massey Cancer Center at Stony Point, Richmond
- VCU Massey Comprehensive Cancer Center, Richmond
Enhancing Oral Cancer Awareness
RekruttererFrivillige helsepersonell ønskes velkommen
- Virginia Commonwealth University, Richmond
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RekruttererFase 3
- VCU Massey Cancer Center, Richmond
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
RekruttererFase 2
- Bon Secours, Richmond
- Virginia Commonwealth University, Richmond
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
RekruttererFase 2
- Massey Cancer Center, Richmond
Plateepitelcancer i hode og hals-studier i andre byer
- Houston, TX47 studier
- Los Angeles, CA42 studier
- Boston, MA40 studier
- New York City, NY39 studier
- Nashville, TN39 studier
- St. Louis, MO28 studier
- Arlington, VA26 studier
- Philadelphia, PA26 studier
- Chicago, IL26 studier
- Atlanta, GA24 studier
- San Antonio, TX22 studier
- New Haven, CT22 studier
Andre studier i Richmond
- Brystkreft26 studier
- Ikke-småcellet lungekreft25 studier
- Prostatakreft19 studier
- Hjertesvikt16 studier
- Lungekreft14 studier
- Kardiovaskulær sykdom13 studier
- Kolorektal kreft13 studier
- Steatotisk leversykdom12 studier
- Akut myelogen leukemi12 studier
- Metastatisk kreft12 studier
- Melanom11 studier
- Fedme11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.